Satellite Symposia

Satellite symposia are non-commercial, grant funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2022. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

Registration, content, and continuing education is the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.

For more information, please contact us.

All times are listed in Central Time (CT).

Tuesday, March 29 | 1:30–3:30pm

Evaluating Treatment Selections for Chronic Spontaneous Urticaria: Managed Care Considerations
  • This activity is provided by Med Learning Group
  • This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
  • This activity is intended for managed care pharmacists, pharmacy directors, physicians, and other health care providers involved in the management of patients with CSU.
  • Contact hours: 1.50 

Program Description 

Join Jonathan Bernstein, MD, and Geoffrey Wall, PharmD, in this interactive MedGames educational  program about the underlying causes and treatments of chronic spontaneous urticaria (CSU).  Game-show style questions will be presented throughout the program regarding several aspects of CSU including the impact of disease, guideline recommended therapy, and clinical data of emerging biologics.  

Learning Objectives

  • Quantify the economic, physical and psychosocial burden of CSU
  • Assess treatment plans for adherence to guideline recommended therapy and consideration of patient-specific factors
  • Evaluate clinical trial data on the efficacy and safety of available and emerging biologics for CSU 

Program Manager
Felecia Beachum
Med Learning Group
fbeachum@medlearninggroup.com 

Registration Link:  
https://www.medlearninggroup.com/cme-programming/csu/

The Foundational Clinical Role and Best Practice Dimensions of Sensor-Based Glycemic Monitoring in the Managed Care Setting: A Practical Roadmap for Establishing and Deploying CGM Across the Medical Spectrum of Diabetes Care
  • Provided by CMEducation Resources
  • Supported by Abbott Diabetes Care  
  • Continuing education credit available for Pharmacists, physicians, NPs, PAs 
  • Contact hours: 1.5 

Program Description 

Join Diana Isaacs, PharmD, Susan Cornell, PharmD, and Christie Schumacher, PharmD, as they discuss real-world examples of how to implement sensor-based continuous glucose monitoring through the managed care pharmacy. They will offer guidance on how to interpret the glucose metrics report (AGP) generated by sensor-based glucose-monitoring technology, the implications for diabetes care in the managed care/HMO setting, and the pharmacoeconomic outcomes and cost analyses associated with sensor-based glucose monitoring (CGM) in persons with diabetes.  

Learning Objectives 

  • Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with diabetes within the managed care environment  
  • Analyze the rationale and evidence for pharmacists recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies in the managed care setting  
  • Compare and contrast available CGM-facilitating monitoring technologies-including their inclusion as a pharmacy or medical benefit in a managed care setting-and pair such technologies with optimal patient profiles. 
  • Discuss the foundational role and practical implementation perspective of sensor-based continuous glucose monitoring in the managed care setting to optimize clinical outcomes, target goal attainment, and comprehensive health metrics in persons across the diabetes spectrum, especially persons with Type 2 diabetes. 
  • Discuss the rationale and practical aspects of applying new CGM technologies and capabilities-including improved device accuracy, alarm features, and integration into electronic health records (EHRs)-to managed care, with a special focus on all persons with diabetes, including those not on insulin therapy 

Program Manager
Milo Falcon
CMEducation Resources
milo.falcon@pharmatecture.net 

Registration Link:  
https://www.reg-cgm.com  

Tuesday, March 29 | 6–8pm

Achieving Appropriate Access for the Treatment of Atopic Dermatitis: Medical and Pharmacy Management Strategies for Managed Care and Payer Professionals
  • Provided by the National Eczema Association, Impact Education, LLC and the Postgraduate Institute for Medicine
  • Supported by Sanofi Genzyme and Regeneron Pharmaceuticals and Pfizer, Inc.
  • 1.5 CME/CNE/CPE credits available
  • The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, registered nurses, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2022 Managed Care and Specialty Pharmacy Annual Meeting. 

Program Description 

Novel treatments and management strategies have the potential to target the underlying pathology resulting in decreased clinical and economic burden for the patient and health care system. However, managed care pharmacists and other payer professionals can lack knowledge of the clinical, economic, and humanistic burden of atopic dermatitis (AD) which can empower them to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes. 

Learning Objectives 

  • Explore the spectrum of clinical, economic, and humanistic burden of AD
  • Review clinical data from recently approved and emerging AD therapies
  • Evaluate benefit design strategies that can contribute to appropriate access and utilization, while simultaneously managing costs and improving treatment outcomes
  • Assess the benefits of multidisciplinary care in AD patients 

Program Manager 
Allison Hartless 
Impact Education, LLC  
allison.hartless@impactedu.net 

Registration Link:
https://www.impactedu.net/amcp2022/

Clinical Breakthroughs in Recurrent Vulvovaginal Candidiasis (RVVC): Managed Care Perspectives
  • Provided by PRIME Education 
  • This activity is supported by an educational grant from Mycovia Pharmaceuticals, Inc. 
  • Continuing education credit available for pharmacists, physicians, physician assistants, nurse practitioners, and nurses 
  • Contact hours: 1.25 

Program Description 

Recurrent vulvovaginal candidiasis (VVC) has serious physical, psychosocial, and economic implications for women worldwide, but awareness and effective treatments are lacking. Fortunately, novel therapies in late stages of development are poised to improve RVVC management and patient quality of life. Join this live symposium as leading experts discuss: 

  • The latest clinical data for novel treatments in development 
  • Patient-centered insights on the broad impact of RVVC on quality of life 
  • Managed care strategies to support RVVC patient care 

Learning Objectives 

  • Evaluate the burden that recurrent vulvovaginal candidiasis (RVVC) imposes on women, including impacts on quality of life and productivity
  • Differentiate the efficacy and safety profiles of emerging treatments for RVVC from the current standard of care
  • Apply key trial data to develop managed care and specialty pharmacy frameworks that ensure patient-centered RVVC treatment and management 

Program Manager 
Lindsey Siegel 
PRIME Education  
meetingsolutions@primeinc.org 

Registration Link:  
https://primeinc.org/live/clinical-breakthroughs-recurrent-vulvovaginal-candidiasis-rvvc-managed-care?utm_source=amcp&utm_medium=webtxt&utm_id=38LV201 

Wednesday, March 30 | 68am

ManagedCareCGM.com Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes
  • Provided by Impact Education, LLC and Medical Education Resources, Inc. 
  • Supported by Dexcom, Inc.  
  • CME/CPE/CNE credit available 
  • The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, registered nurses, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2022 Managed Care and Specialty Pharmacy Annual Meeting. 
  • Contact hours: 1.5 

Program Description 

The true impact of diabetes-related severe hypoglycemia (SH) events is often underestimated by payers, with only approximately 5% of self-reported events among pharmacologically treated patients being captured by health care utilization-based surveillance. Racial/ethnic minority populations and other members affected by SDOH experience further worsening outcomes and resource utilization resulting from type 2 diabetes (T2D), necessitating specialized engagement and intervention. Continuous glucose monitoring (CGM) represents a significant advancement in the precision management of T2D, providing members with the ability to receive a virtually uninterrupted stream of information about the current physiology of their disease. However, many providers cite that prior authorizations delay treatment and negatively impact clinical outcomes. A smart edit featuring an automated look back in claims data for a previous insulin prescription can be used as the criterion for approval with real-time adjudication, easing the administrative burden for payers and providers and streamlining access for members. This approach serves as a basic blueprint for payers to apply the latest evidence in advancing T2D management with optimal outcomes and cost reduction. 

Learning Objectives 

  • Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D 
  • Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among  low-income and racial/ethnic minority populations 
  • Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type  
  • Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care 

Program Manager 
Allison Hartless 
Impact Education, LLC.  
allison.hartless@impactedu.net 

Registration Link:
https://www.managedcarecgm.com/amcp2022/

Optimizing Frontline Immunotherapy Outcomes in NSCLC and Managed Care Considerations 
  • Provided by Pharmacy Times Continuing Education
  • This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc. and Merck Sharp & Dohme Corp.Continuing education credit available for Pharmacists
  • Contact hours: 1.5 

Program Description 

When involved in the treatment and management of patients with non-small cell lung cancer (NSCLC), managed care pharmacists must consider how use of predictive biomarkers can affect patient response to therapy. Several organizations recommend use of biomarker testing before initiating treatment for patients with NSCLC, and managed care professionals can ensure these recommendations are incorporated into treatment protocols. Evidence for first-line treatment regimens with immune checkpoint inhibitors (ICIs) will be presented, as well as considerations for managing immune-mediated adverse effects of therapy. This activity will also explore strategies managed care pharmacists can take to minimize the financial burden associated with use of ICIs in patients with NSCLC. 

Learning Objectives

  • Determine the clinical and economic value of PD-L1 testing in patients with non-small cell lung cancer (NSCLC) who are being considered for frontline treatment with immune checkpoint inhibitors (ICIs).
  • Examine available clinical data related to the frontline use of ICIs in the management of advanced NSCLC.
  • Investigate the impact of ICIs on quality of life and resource utilization associated with frontline use of ICIs in advanced NSCLC. 

Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com 

Registration Link:
https://event.pharmacytimes.org/event/e6e27e4f-c53e-4210-8f43-4f5ba3388650/summary?RefId=nexus-sessions&utm_source=Carousel&utm_medium=banner%20&utm_id=PTCE 

Wednesday, March 30 | 6–8pm

New Horizons in Managing Menopause: Managed Care Considerations for Improved Outcomes
  • Provided by Global Learning Collaborative (GLC)
  • This activity is supported by an independent educational grant from Astellas.
  • Continuing education credit available for managed care professionals and health care providers who manage patients who will undergo menopause
  • Contact hours: 1.5

Summary 

Game on! Test yourself on vasomotor symptoms, from risk factors to management with current and novel treatments, including selective NK3R antagonists. 

Program Description 

Who wants to be an expert? Tune in for a 90-minute interactive live symposium that borrows a popular game show format to test your vasomotor symptom (VMS) management skills. As you play, our expert faculty will offer guidance, context, and recommendations for the medical management of VMS beyond estrogen. Sure, estrogen is currently the most effective treatment for reducing hot flashes and night sweats, but its exact role in taming these symptoms is unclear, and the benefits of therapy must be weighed against risks such as cardiovascular events or uterine and breast cancers. So what else is there? Nonhormonal treatment options are currently being studied and represent a new horizon in terms of options for patients and providers. Play along to make sure you’re up to date on the latest data that can improve the quality of life for your patients.  

Learning Objectives 

  • Discuss data on the individual and public health burden associated with VMS 
  • Describe endocrinologic changes during menopause that lead to the root cause of VMS
  • Compare and contrast the risks and benefits of current treatments for VMS to address barriers to optimal medical management
  • Evaluate the latest clinical trial data on investigational agents for VMS that are nearing approval 

Program Manager 
Anna Trentini 
Global Learning Collaborative (GLC)  
atrentini@ushealthconnect.com 

Registration Links:

Optimizing the Management of Ovarian Cancer – Applying Value-Based Approaches to Clinical Practice
  • Provided by Pharmacy Times Continuing Education 
  • This educational activity is supported by an educational grant from GlaxoSmithKline. Continuing education credit available for Pharmacists 
  • Contact hours: 1.5 

Program Description 

Ovarian cancer is the leading cause of death from gynecologic cancer in the United States. However, in recent years, the development and use of targeted therapies such as PARP inhibitors has contributed to a decreased mortality rate of women with ovarian cancer by about 2% per year. Despite the efficacy of PARP inhibitors, managed care pharmacists must consider several important points regarding their use in ovarian cancer prior to initiation of therapy including genetic testing. This activity will examine unique properties of PARP inhibitors currently approved for ovarian cancer treatment as well as those that are investigational, including line of therapy, BRCA mutation status, adverse effect management, and dosing and administration requirements. Additional evidence-based considerations for approaches to develop and implement oncology clinical pathways to improve delivery of care and manage costs associated with PARP inhibitor therapy for patients with ovarian cancer will be examined to equip managed care professionals to promote optimal medication utilization. 

Learning Objectives 

  • Identify emerging trends in the clinical use of PARP inhibitors for the treatment of ovarian cancer.
  • Explain how the recent trends in use of PARP inhibitors will impact the cost of caring for patients with ovarian cancer.
  • Apply value-based approaches to care to the clinical data supporting the use of PARP inhibitor therapy to optimize the treatment of patients with ovarian cancer. 

Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com 

Registration Link:
https://event.pharmacytimes.org/event/e6e27e4f-c53e-4210-8f43-4f5ba3388650/summary?RefId=nexus-sessions&utm_source=Carousel&utm_medium=banner%20&utm_id=PTCE 

Thursday, March 31 | 68am

Sickle Cell Disease: Discussions on the Challenges and Best Practices to Address the Gaps in Care
  • Provided by Pharmacy Times Continuing Education
  • This activity is supported by an educational grant from Global Blood Therapeutics. Continuing education credit available for Pharmacists
  • Contact hours: 1.5 

Program Description 

Patients with sickle cell disease (SCD) are at risk for developing life-threatening complications and often require hospitalizations. A greater understanding of the pathophysiology of SCD has led to new treatment and management options and has increased the median age of patients with SCD. Managed care professionals need to recognize the potential challenges with the transition of patients with SCD as adults, namely the gaps in access to insurance and medical care. Additionally, patients with SCD who seek symptomatic relief of vaso-occlusive crises with pain management often face stigma, indicating an important opportunity for managed care professionals to evaluate existing protocols and opportunities to ensure equal access to care. This activity will feature a panel of experts who will share perspectives on current treatment challenges and disparities of care affecting people with SCD as well as discuss solutions managed care pharmacists can incorporate into the management plans of patients with SCD. 

Learning Objectives

  • Explore the specific medical needs of patients with sickle cell disease (SCD), including its impact throughout the life cycle.  
  • Compare the clinical data for available and emerging pharmacotherapy for evidence-based management of SCD.
  • Discuss the social determinants of health that are common to patients with SCD and their impact on access to care.
  • Examine the practices and strategies of other managed care organizations in the management of patients with SCD as measured by their health outcomes and the optimization of healthcare resources 

Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com 

Registration Link:  
https://event.pharmacytimes.org/event/e6e27e4f-c53e-4210-8f43-4f5ba3388650/summary?RefId=nexus-sessions&utm_source=Carousel&utm_medium=banner%20&utm_id=PTCE 

The Evolving Management of Relapsed/Refractory Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care Pharmacy Professionals
  • Provided by ProCE, LLC in partnership with Clinical Care Options, LLC 
  • Supported by educational grants from Bristol-Myers Squibb and Karyopharm Therapeutics Inc. 
  • Continuing education credit available for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with relapsed/refractory multiple myeloma, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice 
  • Contact hours: 1.5 

Program Description 

In recent years, exciting progress has been made in relapsed/refractory multiple myeloma. With the expansion of the therapeutic armamentarium, the complexity of care has increased. The choice of the optimal strategy is nuanced and multifaceted, and pharmacists and managed care professionals play an integral role in facilitating access to treatment, therapeutic selection, coordinating clinical support, patient/caregiver education, monitoring, and helping overcome treatment challenges. This activity will review clinical data and guideline recommendations for approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma. Expert panelists will discuss the refinement of treatment selection at first relapse, new indications/approvals and integration into current algorithms, emerging therapies on the horizon, and strategies managed care professionals can use to develop and evaluate clinical pathways to positively impact quality of care while managing costs and factors affecting medication utilization. 

Learning Objectives 

  • Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional collaborative care team in treatment decision-making using available data and patient-related and disease-related factors 
  • Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways  
  • Assist the interprofessional collaborative care team in the supportive care of patients with relapsed/refractory multiple myeloma through early detection and management of treatment-related adverse events 
  • Identify ways managed care pharmacists can promote optimal clinical integration of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to reduce associated costs, decrease hospitalization, and improve outcomes for patients 

Contact Us: 
meetings@clinicaloptions.com   

Registration Link: 
http://www.clinicaloptions.com/ManagedCareMyeloma22

Thursday, March 31 | 6pm8pm

Optimizing Treatment Strategies and Management Approach for Age-Related Macular Degeneration and Diabetic Macular Edema
  • Provided by Pharmacy Times Continuing Education 
  • Supported by Genentech, a member of the Roche Group 
  • Continuing education credit available for Pharmacists 
  • Contact hours: 1.5 

Program Description 

Anti-VEGF antibodies are the mainstay of therapy for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but anti-VEGF therapy requires frequent, repeated intravitreal injections that pose significant burden for patients, caregivers, and the healthcare system. Recent investigation into the angiopoietin (Ang) pathway has the potential to provide a new treatment target that can reduce inflammation in nAMD and DME. Managed care professionals must be able to identify patients who are nonadherent to therapy or in whom initial treatment remains inadequate and consider evidence supporting use of emerging dual-targeted therapies in the management of patients with nAMD and DME. This activity will review clinical data for emerging therapies that target both VEGF and Ang pathways simultaneously. Real-world analyses examining healthcare resource utilization in nAMD and DME will also be discussed, with a focus on the managed care pharmacist’s role in supporting patient adherence, access to treatment, and improving quality of life for patients with nAMD and DME. 

Learning Objectives 

  • Examine the pathophysiology and current treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) and current treatment options 
  • Analyze the efficacy and safety data for emerging therapies and treatment approaches for neovascular AMD and DME 
  • Distinguish the role of managed care professionals in the management and treatment selection for patients with neovascular AMD and DME 

Program Manager 
Crissy Wilson 
Pharmacy Times Continuing Education  
cwilson@pharmacytimes.com 

Registration Link:  
https://event.pharmacytimes.org/event/e6e27e4f-c53e-4210-8f43-4f5ba3388650/summary?RefId=nexus-sessions&utm_source=Carousel&utm_medium=banner%20&utm_id=PTCE

Addressing IgA Nephropathy: Managed Care Considerations for Improved Patient Outcomes
  • Provided by HMP Education
  • Supported by an educational grant from Travere Therapeutics, Inc.
  • Continuing education credit available for physicians, nurses, pharmacists, nurse practitioners, and physician assistants
  • Contact hours: 1.5 

Program Description 

In this session, Dr. Gerald Appel and Dr. Michelle Richardson will describe the pathophysiology, burden, and unmet needs associated with IgAN. They will explain the role of proteinuria in the mechanism of disease of IgAN and the need to target proteinuria in the management of IgAN. Additionally, they will describe the mechanisms of action and the cellular targets of emerging therapies for IgAN. Lastly, they will discuss evidence-based and cost-effective managed care policies for treatments to minimize the burden of IgAN. The faculty will answer audience questions at the end of the session.  

Faculty 

Gerald B. Appel, MD 
Co-Director, Clinical Nephrology 
New York Presbyterian Hospital/Columbia University Medical Center 
Professor of Clinical Medicine 
Columbia University College of Physicians and Surgeons 
Director, Glomerular Kidney Disease Center at Columbia 
New York, New York 

Michelle M. Richardson, PharmD 
Special & Scientific Staff 
William B. Schwartz Division of Nephrology 
Tufts Medical Center 
Boston, Massachusetts 

Learning Objectives 

  • Describe the pathophysiology, burden, and unmet needs associated with IgA nephropathy (IgAN) 
  • Explain the role of proteinuria in the mechanism of disease of IgAN and the need to target proteinuria in the management of IgAN
  • Describe the mechanisms of action and the cellular targets of emerging therapies for IgAN
  • Implement evidence-based and cost-effective managed care policies for treatments to minimize the burden of IgAN 

Program Manager 
Kristin Ciszeski 
HMP Education 
kciszeski@naccme.com 

Registration Link:
https://www.naccme.com/program/22-mcln-101

Friday, Apr. 1 | 68am

The Rapidly Evolving Treatment Landscape for CLL and Focused Updates for Managed Care
  • Provided by Pharmacy Times Continuing Education 
  • Supported by educational grants from Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc. 
  • Continuing education credit available for Pharmacists 
  • Contact hours: 1.5 

Program Description 

Clinical staging and prognostic indicators have an important role in predicting prognosis and guiding treatment decisions for patients with chronic lymphocytic leukemia (CLL). While traditional first-line therapies for CLL have been a combination of chemotherapy and anti-CD20 monoclonal antibodies, current guidelines including oral BTK and BCL-2 inhibitors have changed the treatment landscape. However, there are significant challenges of therapy with these agents for patients, including adverse effects, drug resistance, and economic burden, all of which lead to discontinuation and nonadherence for patients. Managed care pharmacists are well positioned to address these obstacles by utilizing clinical safety and efficacy data of BTK and BCL-2 inhibitors to establish evidence-based protocols for their use in the treatment and management of patients with CLL. Considerations for managed care professionals to mitigate adverse effects of therapy and improve medication adherence will also be discussed. 

Learning Objectives 

  • Analyze the clinical data supporting current therapies and the emerging data of combination therapies for CLL. 
  • Interpret the association between BTK selectivity and the occurrence of toxicities and steps to mitigate these adverse effects. 
  • Investigate the data on treatment options that may improve the economic burden of CLL treatment while optimizing clinical outcomes. 

Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com 

Registration Link:
https://event.pharmacytimes.org/event/e6e27e4f-c53e-4210-8f43-4f5ba3388650/summary?RefId=nexus-sessions&utm_source=Carousel&utm_medium=banner%20&utm_id=PTCE

Clinical and Managed Care Considerations in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Considerations in Addressing Underlying Inflammation
  • Provided by Med Learning Group 
  • Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme 
  • Continuing education credit available for This CME initiative is designed to meet the educational needs of managed care practitioners and other members of the multidisciplinary team including allergists, otolaryngologists, primary care physicians, nurses, nurse practitioners, and pharmacists, to attain an up-to-date understanding of the latest data in management of chronic rhinosinusitis with nasal polyps. 
  • Contact hours: 1 

Program Description 

This whiteboard satellite symposium, which includes faculty-led discussion together with innovative and engaging animations, aims to discuss the costs, patient burden, and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). In this program we will describe the pathophysiology and comorbidities of the disease, take an in-depth look at clinical data on agents that target the underlying inflammation of CRSwNP, and bring to light managed care considerations to help develop the most appropriate and efficacious individualized treatment regimens. 

Learning Objectives 

  • Consider the costs and burdens of chronic rhinosinusitis with nasal polyps (CRSwNP), including pathophysiology and associated comorbidities from a managed care perspective
  • Summarize clinical data and biomarkers concerning the use of novel anti-inflammatory biologics for the management of CRSwNP, including relevant costs of care and managed care considerations
  • Implement best practices for protocolized treatment of CRSwNP through development of individualized treatment plans with a managed care perspective 

Program Manager 
Lisa Crenshaw 
Med Learning Group
lcrenshaw@medlearninggroup.com 

Registration Link: 
http://www.MLG-SYMPO.com